• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌、子宫癌和阴道癌:筛查、治疗概述和预后。

Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis.

机构信息

Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.

Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

出版信息

Med Clin North Am. 2023 Mar;107(2):329-355. doi: 10.1016/j.mcna.2022.10.016. Epub 2023 Jan 2.

DOI:10.1016/j.mcna.2022.10.016
PMID:36759101
Abstract

Ovarian, uterine, and vulvovaginal cancers affect approximately 96,000 women per year in the United States, resulting in approximately 29,000 deaths annually. Routine screening protocols do not detect these malignancies; thus, the recognition of risk factors and evaluation of worrisome symptoms are essential for early detection and improved prognoses. Treatment is managed by gynecologic oncologists, and often involves a combination of surgery, chemotherapy, and possible radiation treatments. Survivor care is managed by the primary-care clinician: expert attention to the mental, physical, and sexual health of each patient will ensure the best outcomes and quality of life.

摘要

在美国,每年约有 96,000 名妇女患有卵巢癌、子宫癌和阴道外阴癌,每年约有 29,000 人死亡。常规筛查方案无法检测到这些恶性肿瘤;因此,识别危险因素和评估令人担忧的症状对于早期发现和改善预后至关重要。治疗由妇科肿瘤学家管理,通常涉及手术、化疗和可能的放射治疗。生存者护理由初级保健临床医生管理:对每位患者的心理、身体和性健康给予专家关注,将确保最佳的结果和生活质量。

相似文献

1
Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis.卵巢癌、子宫癌和阴道癌:筛查、治疗概述和预后。
Med Clin North Am. 2023 Mar;107(2):329-355. doi: 10.1016/j.mcna.2022.10.016. Epub 2023 Jan 2.
2
Correspondence Between Clinician Ratings of Vulvovaginal Health and Patient-Reported Sexual Function After Cancer.癌症治疗后,临床医生对女性外阴阴道健康的评估与患者报告的性功能之间的相关性。
J Sex Med. 2021 Oct;18(10):1768-1774. doi: 10.1016/j.jsxm.2021.07.011. Epub 2021 Aug 24.
3
Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.妇科癌症筛查。外阴、阴道、子宫内膜和卵巢肿瘤。
Prim Care. 1992 Sep;19(3):607-20.
4
Health-related quality of life in early breast cancer.早期乳腺癌患者的健康相关生活质量
Dan Med Bull. 2010 Sep;57(9):B4184.
5
No. 385-Indications for Pelvic Examination.第385号——盆腔检查的适应症
J Obstet Gynaecol Can. 2019 Aug;41(8):1221-1234. doi: 10.1016/j.jogc.2018.12.007.
6
Gynecologic cancer outcomes in the elderly poor: A population-based study.老年贫困人口中的妇科癌症结局:一项基于人群的研究。
Cancer. 2015 Oct 15;121(20):3591-9. doi: 10.1002/cncr.29541. Epub 2015 Jul 31.
7
Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.种族差异对美国因妇科癌症导致的潜在寿命损失年数的影响:基于监测、流行病学和最终结果(SEER)数据库的1975年至2017年趋势
Gynecol Oncol. 2023 Mar;170:266-272. doi: 10.1016/j.ygyno.2023.01.032. Epub 2023 Feb 2.
8
Optimum screening interventions for gynecologic malignancies.妇科恶性肿瘤的最佳筛查干预措施。
Tex Med. 2001 Feb;97(2):49-55.
9
Depressive symptoms and health-related quality of life in older women with gynecologic Cancers.老年妇科癌症患者的抑郁症状与健康相关生活质量。
J Geriatr Oncol. 2020 Jun;11(5):820-827. doi: 10.1016/j.jgo.2019.10.001. Epub 2019 Oct 25.
10
Stevens Johnson Syndrome: Past, Present, and Future Directions Gynecologic Manifestations and Management in SJS/TEN.史蒂文斯-约翰逊综合征:过去、现在及未来方向——SJS/TEN中的妇科表现与管理
Front Med (Lausanne). 2022 Jul 4;9:874445. doi: 10.3389/fmed.2022.874445. eCollection 2022.

引用本文的文献

1
Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment.线粒体Magmas蛋白在卵巢癌中表达增强:抑制Magmas可促进抗肿瘤作用,为卵巢癌治疗提供新方法。
Cells. 2025 Apr 29;14(9):655. doi: 10.3390/cells14090655.
2
Gemcitabine-Doxorubicin Combination Polymer-Drug Conjugate Prepared by SPAAC Click Chemistry: In Vitro Characterization.通过 SPAAC 点击化学制备的吉西他滨 - 阿霉素组合聚合物 - 药物偶联物:体外表征
Int J Mol Sci. 2025 Mar 20;26(6):2798. doi: 10.3390/ijms26062798.
3
Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis.
血管生成抑制剂联合聚ADP核糖聚合酶抑制剂在晚期卵巢癌维持治疗中的疗效和安全性:一项荟萃分析。
Front Oncol. 2024 Nov 18;14:1477105. doi: 10.3389/fonc.2024.1477105. eCollection 2024.
4
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on drug response genes to predict prognosis and therapeutic response in ovarian cancer.单细胞和批量RNA测序的综合分析基于药物反应基因鉴定出一种特征,以预测卵巢癌的预后和治疗反应。
Heliyon. 2024 Jun 20;10(13):e33367. doi: 10.1016/j.heliyon.2024.e33367. eCollection 2024 Jul 15.
5
Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines.卵巢癌临床指南:韩国妇科肿瘤学会指南。
J Gynecol Oncol. 2024 Jan;35(1):e43. doi: 10.3802/jgo.2024.35.e43. Epub 2023 Dec 27.
6
Identifying Explainable Machine Learning Models and a Novel SFRP2 Fibroblast Signature as Predictors for Precision Medicine in Ovarian Cancer.鉴定可解释的机器学习模型和新型 SFRP2 成纤维细胞特征作为卵巢癌精准医疗的预测因子。
Int J Mol Sci. 2023 Nov 29;24(23):16942. doi: 10.3390/ijms242316942.
7
Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.PARP 抑制剂维持治疗对新诊断的晚期上皮性卵巢癌的影响:一项荟萃分析。
PLoS One. 2023 Nov 17;18(11):e0294647. doi: 10.1371/journal.pone.0294647. eCollection 2023.
8
Pain nursing for gynecologic cancer patients.妇科癌症患者的疼痛护理
Front Oncol. 2023 Jul 26;13:1205553. doi: 10.3389/fonc.2023.1205553. eCollection 2023.
9
Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis.病毒感染与肿瘤发生在子宫颈癌病因学和发病机制中的意义。
Front Microbiol. 2023 May 24;14:1194431. doi: 10.3389/fmicb.2023.1194431. eCollection 2023.